Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

DESIGN OF EXPERIMENTS OPTIMIZATION IN THE FORMULATION OF CORTICOSTEROID NANOCRYSTALS FOR OPTHALMIC DRUG DELIVERY

Frederico Barros – Pharmaceutical Process Development Specialist, EUROAPI; Gabriela Bordon – Research Fellow, Karlsruhe Institute of Technology; Kelvin Hartanto – Student, Queen's university Belfast; Luc Kalshoven – Senior project manager, EUROAPI; Lucia Lopez-vidal – Research Fellow, Queen's university Belfast; Braham Mezghrani – Senior project manager, EUROAPI; Alejandro Paredes – Senior Lecturer, Queen's university Belfast
Introduction: Inflammatory eye disease is a complex condition that accounts for 15% of preventable blindness1. The first line of treatment for this disease are topical corticosteroids, which are highly hydrophobic substances. In addition, static and dynamic physiological barriers in the eye impede drug absorption resulting in only 5% bioavailability of conventional dosage forms like eyedrops or ointments2. This project aims to provide solutions by developing optimized nanocrystals (NCs) formulation of Triamcinolone acetonide and Prednisolone using a Design of Experiments (DoE) approach to increase dissolution rate and saturation solubility and providing a predictive model to control particle size.

Learning Objectives:

  • See nanocrystals as an elegant technology to increase dissolution rate of hydrophobic drugs.
  • understand that predictive models in NCs formulation identify critical quality attributes for production